Nowa wersja platformy jest już dostępna.
Przejdź na https://bibliotekanauki.pl

PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2010 | nr 4 (1) | 311-325
Tytuł artykułu

Fibrilácia predsiení - epidémia 21. storočia

Treść / Zawartość
Warianty tytułu
Atrial Fibrillation - an Epidemic of the 21 Century
Języki publikacji
SK
Abstrakty
EN
Atrial fibrillation is a most common sustained cardiac arrhythmia. It causes higher morbidity and mortality, higher stroke frequency and tromboembolism as well as hemodynamic disturbances that impair physical tolerance and can worse the heart failure. There are two ways how to manage atrial fibrillation: to restore and to maintain the sinus rhythm or to control the heart rate. Both strategies can be realized in pharmacological or non-pharmacological way. Although the use of the antiarrhythmics is still dominant in case of atrial fibrillation, the use of nonpharmacological methods like pacing, ablation and surgery are more and more frequent.(original abstract)
Słowa kluczowe
PL
EN
Rocznik
Numer
Strony
311-325
Opis fizyczny
Bibliografia
  • Lip GYH. Atrial Fibrillation in Clinical Practice. London: Martin Dunitz Ltd, 2001; 234.
  • Gersh BJ, Tsang TSM, Barnes ME et al. The changing epidemiology of non- valvular atrial fibrillation: the role of novel risk factors. Eur Heart J 2005; 7 (Suppl C): C5-C11.
  • Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. Eur Heart J 2006; 27: 1979 - 2030.
  • Psaty BM, Manolio TA Kuler LH, et al. Incidence and risk factors for atrial fibrillation inolder adults. Circulation 1997; 96: 2455-2461.
  • Schweikert RA, Kidwel G. Tachyarrhythmias. In. Marso SP, Griffin BP, Topol EJ. Manual of Cardiovascular medicine. Philadelphia: Lipincott Williams&Wilkins, 2000; 249-280.
  • Kalist P, Pella J. Klinické prejavy fibrilácie predsiení. In: Fibrilácia predsiení. Základné fakty. Košice: Oriens s.r.o., 2002; 10.
  • De Simone A, De Pasquale M, De Matteis C, et al. Verapamil Plus Antiarrhythmic drugs Reduce Atrial Fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur Heart J 2003; 24: 1425- 1429.
  • Kmec J. Farmakoterapia supraventrikulárnych arytmií. Via pract. 2008; 5 (6): 237-240.
  • Richard Ph, Yaici K, Rinaldi JP, et al. Cardioversion of atrial fibrillation: how and when? Eur Heart J 2003; 5 (Suppl H): H40 - H44.
  • Stoddard MF, Dawkins PR, Prince CR, et al. Left atrial appendage is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452-459.
  • Mathew TP, Moore A, McIntyre M, et al. Randomised comparison of electrode positions for cardioversion of atrial fibrillation. Heart 1999; 81: 576-579.
  • Kmec J. Porovnanie účinnosti monofázickej a bifázickej elektrickej kardioverzie u pacientov s perzistujúcou fibriláciou predsiení. Cardiol 2006; 5: 265-278.
  • Kmec J. Praktické aspekty elektrickej kardioverzie u pacientov s perzistujúcou fibriláciou predsiení. Kardiol. prax 2007; 5 (3): 163-174.
  • Kmec J. Prechodná strata komorovej stimulácie u pacienta po synchrónnej bifázickej elektrickej kardioverzii pre perzistujúci flutter predsiení. Kardiol. prax 2008; 6 (2):115-117.
  • Capucci A, Aschieri D. Antiarrhythmic drug therapy: what is certain and what is to come. Eur Heart J 2003; 5 (Suppl): H8-H18.
  • Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM). Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
  • Deedwania PC, Singh BN, Ellenbogen, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574-2579.
  • Kober L, Torp-Pedersen C. Atrial fibrillation and heart failure: Aetiological, prognostic and therapeutic considerations In: McMurray JJV, Pfeffer MA. Heart failure Updates. London: Taylor & Francis, 2003; 59-78.
  • Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation. NEJM 2008; 25(358): 2667-2677.
  • Køber L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678- 2687
  • Kautzner J, Peichl P. Praktické aspekty léčby fibrilace síní: Nefarmakologické postupy. Interní medicína pro praxi 2004; 4: 194-199.
  • Kmec J, Slanina M. Nefarmakologické stratégie liečby fibrilácie predsiení - kardiostimulačná a ablačná liečba. Lek Obz 2006; 5: 213-219.
  • Kmec J. Nefarmakologické stratégie liečby fibrilácie predsiení - chirurgická a hybridná liečba. Lek Obz 2006; 6: 244 -249.
  • Lesh MD, Kalman JM, Roithinger FX, Karch M.R. Potential role of "hybrid therapy" for atrial fibrillation. Semin Interv Cardiol 1997; 2: 267- 271.
  • Feld GK. New approaches for the management of atrial fibrillation. Role of ablation atrial flutter. J Cardiovasc Electrophysiol 1999; 10: 1188-1191.
  • Bath PhMV, Zhao L, Heptinstall S. Current status of stroke prevention in patients with atrial fibrillation. Eur Heart J 2005; 7 (Suppl C): C12-C18.
  • Kmec J, Novotný R, Beňová K, Čanda I. Antitrombotická liečba fibrilácie predsiení. Causa Subita 2007, číslo 5, ročník 10, s. 123-128.
  • Gage BF, Watterman AD, Shannon W a spol. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
  • Zimetbaum P.J, Josephson M.E. Practical Clinical Electrophysiology. Philadelphia: Lippincott Williams &Wilkins, a Wolters Kluwert busines, 2009, 304.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.ekon-element-000171336565
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.